EMA Guidance On Investigational ATMPs To Focus On Exploratory And Pivotal Trials
Executive Summary
The European Medicines Agency believes that advanced therapy medicinal product makers need better guidance on differentiating between exploratory and pivotal trials.
You may also be interested in...
EU Guideline On Investigational ATMPs Delayed Until Q3 2019
Several factors have contributed towards a delay in the European Medicines Agency's much awaited guideline on investigational advanced therapy medicinal products, which was initially due to be finalized in the second quarter of 2017.
EMA's Action Plan To Support ATMPs Expected In Jan 2017
The European Medicines Agency's action plan to support the development of advanced therapy medicinal products will prioritize on actions that are feasible, will result in major gains without the need for a lot of effort and will not require legislative changes.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.